Domestic purchasing channels and related information of Apelix

Alpelisib (Alpelisib) is an important targeted therapy drug for specific types of breast cancer and belongs to the PI3K inhibitor (phosphoinositide 3-kinase inhibitor) category. The drug specifically targets tumors with PIK3CA mutations that have been confirmed by an FDA-approved test. Since being approved by the FDA in 2019, Apelvis has become the first PI3K inhibitor approved for the treatment of specific breast cancers.

Apelix plays an important role in the treatment of metastatic breast cancer, which is breast cancer that has spread to organs in the body other than the breast. Especially when the patient's breast cancer is hormone receptor positive and the disease continues to worsen despite hormone therapy, Apelvis has become a key treatment option. This medicine is available in tablet form and contains the active ingredient alpelisib. The recommended dose is 300 mg (two 150 mg tablets) per day, to be taken with food.

However, the original drug of Apelvis has not yet been launched in China, which means that domestic patients cannot purchase this drug directly through conventional channels such as hospital pharmacies. However, there are some other options available for patients who desperately need this drug. In places such as Europe and India, the original version of Apelvis is already on the market, and patients can purchase it from these regions through legal channels. In addition, there are also some generic versions of Apelvis on the market, such as the generic version produced by Lucius Pharmaceuticals in Laos. Its drug ingredients are basically the same as the original drug, providing patients with more choices.

It should be noted that no matter which way to purchase Apelvis, patients should ensure that the source of the drug is legal, of reliable quality, and used under the guidance of a doctor.